- Investopedia•27 minutes ago
Corbus's anti-inflammatory drug, anabasum, met the primary endpoint for safety and tolerability in Phase 2.
- Investor's Business Daily•37 minutes ago
Vertex Pharma saw its IBD SmartSelect Composite Rating rise to 97 Thursday, up from 92 the day before.
- Barrons.com•1 hour ago
Yesterday, we at Barron's took a victory lap after Vertex Pharmaceuticals (VRTX) soared 20% after releasing data from its cystic fibrosis drug trial that was deemed a success. While many sell-side analysts seem to think it was, but not H.C. Wainwright's Andrew Fein and Emile Yu, who write that "calling results strong does not make them so." They explain why: In yesterday’s investor call following results from the EVOLVE and EXPAND studies of the tez/iva (661/770) combo, management highlighted their view that “the 4% is different than the 2.8%”.
VRTX : Summary for Vertex Pharmaceuticals Incorpor - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||108.24 x 300|
|Ask||108.32 x 300|
|Day's Range||106.52 - 109.73|
|52 Week Range||71.46 - 111.88|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-236.21|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|